MCID: DMY004
MIFTS: 57

Demyelinating Disease

Categories: Neuronal diseases

Aliases & Classifications for Demyelinating Disease

MalaCards integrated aliases for Demyelinating Disease:

Name: Demyelinating Disease 12 76 15
Demyelinating Diseases 55 44 73
Demyelinating Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3213
MeSH 44 D003711
NCIt 50 C34527
ICD10 33 G37.9
UMLS 73 C0011303

Summaries for Demyelinating Disease

MalaCards based summary : Demyelinating Disease, also known as demyelinating diseases, is related to allergic encephalomyelitis and balo concentric sclerosis. An important gene associated with Demyelinating Disease is MBP (Myelin Basic Protein), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Prednisone and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and bone, and related phenotypes are Reduced mammosphere formation and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 A demyelinating disease is any disease of the nervous system in which the myelin sheath of neurons is... more...

Related Diseases for Demyelinating Disease

Diseases related to Demyelinating Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 333)
# Related Disease Score Top Affiliating Genes
1 allergic encephalomyelitis 32.4 MBP MOG PLP1
2 balo concentric sclerosis 32.1 AQP4 IFNB1 MBP MOG
3 neuromyelitis optica 31.4 AQP4 IL17A MBP MOG
4 acute transverse myelitis 31.2 AQP4 IL10 MMP9
5 multiple sclerosis 31.2 AQP4 CCL2 CCL3 CXCL10 ICAM1 IFNB1
6 optic neuritis 30.5 AQP4 MBP MOG PLP1 TNF
7 encephalitis 30.3 AQP4 CCL2 CXCL10 IL1B MOG
8 neuritis 30.1 AQP4 CCL2 CXCL10 IFNG IL1B MBP
9 myelitis 30.0 AQP4 IL17A MBP MOG TNF
10 acute disseminated encephalomyelitis 30.0 AQP4 IL10 IL1B MBP MOG
11 myasthenia gravis 29.9 IFNG IL10 MBP TNF
12 guillain-barre syndrome 29.9 MBP TNF TNFRSF1A
13 transverse myelitis 29.9 AQP4 IL10 IL17A MBP MMP9 TNF
14 viral infectious disease 29.9 CCL3 CXCL10 IFNB1 IFNG IL10 IL1B
15 intracranial hypertension 29.8 AQP4 IL1B TNF
16 hematopoietic stem cell transplantation 29.8 IFNG IL10 TNF
17 arthritis 29.6 CCL2 IFNG IL10 IL17A IL1B MMP9
18 peripheral nervous system disease 29.6 AQP4 MBP MOG TNF
19 psoriatic arthritis 29.6 IL17A IL1B TNF TNFRSF1A
20 rheumatic disease 29.6 IFNG IL10 IL1B TNF
21 leprosy 3 29.6 IFNG IL10 TNF
22 brucellosis 29.6 IFNG IL10 TNF
23 hepatitis a 29.6 IFNG IL10 TNF
24 inflammatory bowel disease 29.4 CCL2 CXCL10 ICAM1 IFNG IL10 IL17A
25 q fever 29.4 IFNG IL10 IL1B TNF
26 colitis 29.3 IFNG IL10 IL17A IL1B TNF
27 acquired immunodeficiency syndrome 29.3 CCL3 IFNG IL10 IL1B TNF
28 psoriasis 29.3 CCL2 CXCL10 ICAM1 IFNG IL10 IL17A
29 viral encephalitis 29.2 CCL2 CXCL10 IL10 IL1B MBP MOG
30 uveitis 29.2 CCL2 CXCL10 ICAM1 IFNG IL10 IL17A
31 behcet syndrome 29.2 CCL3 IFNG IL10 IL17A IL1B TNF
32 rheumatoid arthritis 29.1 CCL2 CCL3 ICAM1 IFNG IL10 IL17A
33 optic atrophy with demyelinating disease of cns 12.0
34 central pontine myelinolysis 11.2
35 epileptic encephalopathy, early infantile, 39 11.2
36 leukodystrophy, demyelinating, adult-onset, autosomal dominant 11.0
37 multiple sclerosis 5 10.8
38 multiple sclerosis 3 10.8
39 megalencephalic leukoencephalopathy with subcortical cysts 1 10.8
40 myelinoclastic diffuse sclerosis 10.8
41 adrenoleukodystrophy 10.6
42 purulent labyrinthitis 10.4 CCL2 IL1B
43 herpes simplex virus keratitis 10.4 CCL2 ICAM1
44 diabetic foot ulcers 10.4 CCL2 MMP9
45 leukodystrophy, hypomyelinating, 5 10.4
46 chronic follicular conjunctivitis 10.4 IL1B MMP9
47 aortic aneurysm, familial abdominal, 1 10.3 CCL2 IL1B MMP9
48 exudative glomerulonephritis 10.3 IL1B TNF
49 brain edema 10.3 AQP4 IL1B MMP9
50 keratitis, hereditary 10.3 IL17A IL1B MMP9

Graphical network of the top 20 diseases related to Demyelinating Disease:



Diseases related to Demyelinating Disease

Symptoms & Phenotypes for Demyelinating Disease

GenomeRNAi Phenotypes related to Demyelinating Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.56 ABCD1 CCL2 CCL3 IL17A MOG NTF3
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 ICAM1 IL10 IL17A IL1B TNF TNFRSF1A
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 ICAM1 IL10 IL17A IL1B NTF3 TNF

MGI Mouse Phenotypes related to Demyelinating Disease:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.44 ABCD1 AQP4 CXCL10 ICAM1 IFNB1 IFNG
2 immune system MP:0005387 10.43 ABCD1 AQP4 CCL2 CXCL10 ICAM1 IFNB1
3 homeostasis/metabolism MP:0005376 10.4 ABCD1 AQP4 CXCL10 ICAM1 IFNB1 IFNG
4 growth/size/body region MP:0005378 10.37 AQP4 ICAM1 IFNG IL10 IL17A IL1B
5 cellular MP:0005384 10.34 CXCL10 ICAM1 IFNG IL10 IL7R MBP
6 mortality/aging MP:0010768 10.33 ABCD1 AQP4 CXCL10 ICAM1 IFNG IL10
7 behavior/neurological MP:0005386 10.32 ABCD1 AQP4 IFNG IL10 MBP MMP9
8 cardiovascular system MP:0005385 10.27 AQP4 CXCL10 ICAM1 IFNG IL10 IL1B
9 nervous system MP:0003631 10.27 ABCD1 AQP4 CXCL10 ICAM1 IFNB1 IFNG
10 endocrine/exocrine gland MP:0005379 10.24 ABCD1 AQP4 ICAM1 IFNG IL10 IL17A
11 digestive/alimentary MP:0005381 10.2 AQP4 ICAM1 IFNG IL10 IL17A MMP9
12 neoplasm MP:0002006 10.1 ICAM1 IFNB1 IFNG IL10 IL1B IL7R
13 muscle MP:0005369 10.09 ICAM1 IFNG IL10 MMP9 MOG NTF3
14 no phenotypic analysis MP:0003012 9.92 AQP4 IFNB1 IFNG IL10 IL17A PTPRC
15 reproductive system MP:0005389 9.91 ABCD1 IFNG IL10 MBP MMP9 NTF3
16 respiratory system MP:0005388 9.81 AQP4 IFNG IL10 IL17A MMP9 NTF3
17 skeleton MP:0005390 9.65 IFNB1 IFNG IL10 IL17A IL1B MMP9
18 vision/eye MP:0005391 9.4 ABCD1 AQP4 ICAM1 IFNG IL10 MBP

Drugs & Therapeutics for Demyelinating Disease

Drugs for Demyelinating Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 634)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
2
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3,Early Phase 1 24280-93-1 446541
3
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
5
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
6
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
7
Natalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 189261-10-7
8
4-Aminopyridine Approved Phase 4,Phase 3,Phase 2 504-24-5 1727
9
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 145155-23-3
10
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 65271-80-9 4212
11
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 174722-31-7 10201696
12
Interferon beta-1a Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 145258-61-3 6438354
13
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 216503-57-0
14
Titanium dioxide Approved Phase 4,Phase 2 13463-67-7
15
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
16 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
18
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3 19982-08-2 4054
19
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
20
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 453 6251
21
leucovorin Approved Phase 4,Phase 3,Phase 1,Early Phase 1 58-05-9 6006 143
22
Methotrexate Approved Phase 4,Phase 3,Early Phase 1 59-05-2, 1959-05-2 126941
23
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 112111-43-0
24
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 68693-11-8 4236
25
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
26
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
27
Phytonadione Approved, Investigational Phase 4,Phase 3 84-80-0 4812 5284607
28
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 624-49-7 637568 5271565
29
Montelukast Approved Phase 4,Phase 1,Phase 2 158966-92-8 5281040
30
Acyclovir Approved Phase 4,Phase 3,Phase 1 59277-89-3 2022
31
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
32
Cetirizine Approved Phase 4,Phase 1,Phase 2 83881-51-0 2678
33
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-45-6, 75614-87-8 774
34
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103-90-2 1983
35
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
36
Ranitidine Approved Phase 4,Phase 3 66357-35-5, 66357-59-3 3001055
37
Aspirin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 50-78-2 2244
38
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
39
Peppermint oil Approved, Investigational Phase 4,Phase 3 8006-90-4
40
Ethanol Approved Phase 4,Phase 3 64-17-5 702
41
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078
42
Peppermint Approved Phase 4,Phase 3
43
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
44
Tocopherol Approved, Investigational Phase 4,Phase 2,Phase 1 1406-66-2 14986
45
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
46
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
47
Iron Approved Phase 4,Early Phase 1 7439-89-6 23925
48
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
49
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
50
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592

Interventional clinical trials:

(show top 50) (show all 2018)
# Name Status NCT ID Phase Drugs
1 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
2 IVIg for Demyelination in Diabetes Mellitus Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
3 Methylprednisolone During the Switch Between Natalizumab and Fingolimod Unknown status NCT02769689 Phase 4 Methylprednisolone;Placebo;natalizumab (NTZ);fingolimob (FTY)
4 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
5 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
6 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Unknown status NCT02259361 Phase 4 Sustained-release oral dalfampridine;Placebo
7 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
8 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4 Drug: placebo
9 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
10 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
11 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
12 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
13 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4 Betaseron;Copaxone
14 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
15 Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
16 A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 Completed NCT01715831 Phase 4 DMARDs;Tocilizumab
17 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
18 Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy Completed NCT03091569 Phase 4
19 Natalizumab Temporary Discontinuation Study Completed NCT02775110 Phase 4
20 Tecfidera and the Gut Microbiota Completed NCT02471560 Phase 4 dimethyl fumarate;injectable MS DMT
21 Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients Completed NCT02146534 Phase 4 extended release fampridine;Placebo
22 MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia Completed NCT01556685 Phase 4
23 A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone® Completed NCT00239993 Phase 4 glatiramer acetate
24 BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Completed NCT03269175 Phase 4
25 Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) Completed NCT02720107 Phase 4
26 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Completed NCT02683863 Phase 4 BG00012 (DMF) (Tecfidera®.)
27 Plegridy Satisfaction Study in Participants Completed NCT02587065 Phase 4 peginterferon beta-1a
28 Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® Completed NCT02499900 Phase 4 Copaxone®
29 Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis Completed NCT02461069 Phase 4 Dimethyl fumarate
30 Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera Completed NCT02410278 Phase 4 dimethyl fumarate;montelukast;Placebo
31 Fingolimod Effect on Cytokine and Chemokine Levels Completed NCT02373098 Phase 4 Fingolimod 0.5 mg
32 Long-term Follow-up of Fingolimod Phase II Study Patients Completed NCT02307838 Phase 4
33 A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Completed NCT02208050 Phase 4 Fampridine;Placebo
34 Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA Completed NCT02205489 Phase 4 Alemtuzumab GZ402673;cetirizine;ranitidine;methylprednisolone;methylprednisolone;aciclovir;esomeprazole;ibuprofen;paracetamol
35 Resistance Training and Amino Pyridine in Multiple Sclerosis Completed NCT02143167 Phase 4 SR-fampridine;Placebo
36 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Completed NCT02142205 Phase 4
37 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4 dimethyl fumarate
38 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis Completed NCT02090413 Phase 4 dimethyl fumarate;acetylsalicylic acid;ASA-Placebo
39 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis Completed NCT02064816 Phase 4 Rebif®;Rebif®
40 Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS Completed NCT02048072 Phase 4 Gilenya
41 Rebif® Rebidose® Versus Rebiject II® Ease-of-Use Completed NCT02019550 Phase 4
42 Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse Completed NCT01986998 Phase 4 Methylprednisolone 1250 mg/24h x3 days;Oral Methylprednisolone 625 mg/24h x3 days
43 Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients Completed NCT01968902 Phase 4
44 A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients Completed NCT01964547 Phase 4 Sativex;Placebo
45 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
46 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4 Teriflunomide
47 Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations Completed NCT01888354 Phase 4 H.P. Acthar Gel (repository corticotropin injection)
48 Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States Completed NCT01873417 Phase 4 BG00012 (DMF)
49 Efficacy of Fish Oil in Multiple Sclerosis Completed NCT01842191 Phase 4
50 Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications Completed NCT01834586 Phase 4 Anesthetic Topical Adhesive Synera

Search NIH Clinical Center for Demyelinating Disease

Cochrane evidence based reviews: demyelinating diseases

Genetic Tests for Demyelinating Disease

Anatomical Context for Demyelinating Disease

MalaCards organs/tissues related to Demyelinating Disease:

41
T Cells, Brain, Bone, Spinal Cord, Testes, Eye, Bone Marrow

Publications for Demyelinating Disease

Articles related to Demyelinating Disease:

(show top 50) (show all 950)
# Title Authors Year
1
Demyelinating disease: Cholesterol crystals thwart repair in old CNS. ( 29391584 )
2018
2
Mast Cells and Innate Lymphoid Cells: Underappreciated Players in CNS Autoimmune Demyelinating Disease. ( 29619025 )
2018
3
Occipital neuralgia associates with high cervical spinal cord lesions in idiopathic inflammatory demyelinating disease. ( 29629601 )
2018
4
Dissecting the multifactorial nature of demyelinating disease. ( 29722306 )
2018
5
Correction to: Protective and therapeutic role of 2-carbacyclic phosphatidic acid in demyelinating disease. ( 29506553 )
2018
6
microRNA-219 Reduces Viral Load and Pathologic Changes in Theiler's Virus-Induced Demyelinating Disease. ( 29433936 )
2018
7
Neutropenia as a Complication of Tumefactive Demyelinating Disease: A Case Report. ( 29330070 )
2018
8
Effects of Keratinocyte-Derived Cytokine (CXCL-1) on the Development of Theiler's Virus-Induced Demyelinating Disease. ( 29410948 )
2018
9
Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. ( 29421990 )
2018
10
MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis. ( 29438836 )
2018
11
Fatal demyelinating disease is induced by monocyte-derived macrophages in the absence of TGF-I^ signaling. ( 29662171 )
2018
12
Immunoregulation of Theiler's virus-induced demyelinating disease by glatiramer acetate without suppression of antiviral immune responses. ( 29362931 )
2018
13
CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. ( 29455184 )
2018
14
Recurrent Optic Neuritis as the Initial Symptom in Demyelinating Diseases. ( 29856159 )
2018
15
Migraine as possible red flag of PFO presence in suspected demyelinating disease. ( 29801894 )
2018
16
Concurrence of juvenile idiopathic arthritis and primary demyelinating disease in a young child. ( 30300848 )
2018
17
Helicobacter pylori infection and demyelinating disease of the central nervous system. ( 29983199 )
2018
18
Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease. ( 30047830 )
2018
19
Adult-onset hemophagocytic lymphohistiocytosis type 2 presenting as a demyelinating disease. ( 30053752 )
2018
20
Value of 18F-FET PET in Patients With Suspected Tumefactive Demyelinating Disease-Preliminary Experience From a Retrospective Analysis. ( 30153143 )
2018
21
Teriflunomide's Effect on Glia in Experimental Demyelinating Disease: A Neuroimaging and Histologic Study. ( 30232810 )
2018
22
Perivascular enhancement in anti-MOG antibody demyelinating disease of the CNS. ( 30297517 )
2018
23
Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma. ( 30311534 )
2018
24
Early IFNγ-Mediated and Late Perforin-Mediated Suppression of Pathogenic CD4 T Cell Responses Are Both Required for Inhibition of Demyelinating Disease by CNS-Specific Autoregulatory CD8 T Cells. ( 30356717 )
2018
25
Tuftsin Combines With Remyelinating Therapy and Improves Outcomes in Models of CNS Demyelinating Disease. ( 30555470 )
2018
26
The Impact of Post-Genomics Approaches in Neurodegenerative Demyelinating Diseases: The Case of Guillain-Barré Syndrome. ( 29542408 )
2018
27
Comment on "Central Demyelinating Diseases After Vaccination Against Hepatitis B Virus: A Disproportionality Analysis Within the VAERS Database". ( 30269242 )
2018
28
Authors' Reply to Cohen et al.'s Comment on "Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database". ( 30269243 )
2018
29
Optical coherence tomography in central nervous system demyelinating diseases related optic neuritis. ( 30364209 )
2018
30
Detection of aquaporin-4 antibodies for patients with CNS inflammatory demyelinating diseases other than typical MS in Lithuania. ( 30284401 )
2018
31
Lessons From Leprosy: Peripheral Neuropathies and Deformities in Chronic Demyelinating Diseases. ( 30177357 )
2018
32
Experimental Models of Autoimmune Demyelinating Diseases in Nonhuman Primates. ( 28583039 )
2018
33
Neuropsychological outcomes of pediatric demyelinating diseases: a review. ( 28637379 )
2018
34
Psychiatric disorders in children with demyelinating diseases of the central nervous system. ( 28675955 )
2018
35
Health-Related Quality of Life in Pediatric Patients With Demyelinating Diseases: Relevance of Disability, Relapsing Presentation, and Fatigue. ( 29049805 )
2018
36
Clinical course of MOG antibody-associated recurrent demyelinating diseases. ( 29175896 )
2018
37
Activating transcription factor 6α deficiency exacerbates oligodendrocyte death and myelin damage in immune-mediated demyelinating diseases. ( 29436030 )
2018
38
Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis. ( 29454521 )
2018
39
New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases. ( 29524760 )
2018
40
Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database. ( 29560597 )
2018
41
Paediatric multiple sclerosis and other acute demyelinating diseases. ( 29629942 )
2018
42
Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis. ( 29665426 )
2018
43
Classification and diagnostic criteria for demyelinating diseases of the central nervous system: Where do we stand today? ( 29673575 )
2018
44
Demyelinating diseases. ( 29903398 )
2018
45
Microglia P2X4 receptors as pharmacological targets for demyelinating diseases. ( 30037978 )
2018
46
Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: An ethnicity influence? ( 30056361 )
2018
47
A tale of two demyelinating diseases and Zika virus. ( 30226108 )
2018
48
Role of developmental venous anomalies in etiopathogenesis of demyelinating diseases. ( 30238820 )
2018
49
Inflammatory demyelinating diseases of the central nervous system in Niger. ( 30270137 )
2018
50
Follicular Development and Secretion of Ovarian Hormones during the Juvenile and Adult Reproductive Lives of the Myelin Mutant taiep Rat: An Animal Model of Demyelinating Diseases. ( 30363667 )
2018

Variations for Demyelinating Disease

Expression for Demyelinating Disease

Search GEO for disease gene expression data for Demyelinating Disease.

Pathways for Demyelinating Disease

Pathways related to Demyelinating Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 CCL2 CCL3 CXCL10 ICAM1 IFNB1 IFNG
2
Show member pathways
13.91 CCL2 CCL3 CXCL10 IL10 IL17A IL1B
3
Show member pathways
13.77 CCL2 CCL3 CXCL10 IFNB1 IFNG IL10
4
Show member pathways
13.63 CCL2 CCL3 ICAM1 IFNB1 IFNG IL10
5
Show member pathways
13.5 CCL2 CCL3 CXCL10 IL10 IL17A IL1B
6
Show member pathways
13.4 CCL2 CCL3 CXCL10 IL10 IL17A IL1B
7
Show member pathways
13.38 CCL2 CCL3 CXCL10 ICAM1 IFNB1 IFNG
8
Show member pathways
13.17 CCL2 CCL3 ICAM1 IFNB1 IL1B MMP9
9
Show member pathways
13.12 CCL2 CCL3 CXCL10 IFNB1 IFNG IL10
10
Show member pathways
12.99 ICAM1 IFNG IL10 IL17A IL1B PTPRC
11
Show member pathways
12.92 CCL2 CXCL10 ICAM1 IFNB1 IFNG IL1B
12
Show member pathways
12.81 CXCL10 IFNB1 IFNG IL1B TNF
13
Show member pathways
12.7 CCL2 IFNG IL10 IL17A IL1B TNF
14
Show member pathways
12.69 IFNG IL10 PTPRC TNF TNFRSF1A
15
Show member pathways
12.66 IFNG IL10 IL17A IL1B TNF
16 12.64 CCL2 CXCL10 IFNG IL10 IL17A IL1B
17
Show member pathways
12.55 IFNG IL10 IL17A IL1B PTPRC TNF
18
Show member pathways
12.48 IFNB1 IFNG IL10 IL7R PTPRC
19
Show member pathways
12.48 CCL2 CXCL10 IFNG IL17A IL1B MMP9
20
Show member pathways
12.43 CCL2 ICAM1 IFNG IL1B TNF
21
Show member pathways
12.4 IFNB1 IFNG IL10 IL17A IL1B NTF3
22
Show member pathways
12.37 IFNG IL10 IL1B TNF TNFRSF1A
23 12.36 IFNB1 IFNG IL10 IL1B TNF TNFRSF1A
24 12.34 CXCL10 ICAM1 IFNB1 TNF
25
Show member pathways
12.33 IFNB1 IFNG IL1B TNF TNFRSF1A
26
Show member pathways
12.31 CXCL10 IFNB1 IFNG IL1B TNF
27
Show member pathways
12.3 CCL2 CCL3 CXCL10 ICAM1 IL1B MMP9
28 12.3 AQP4 IL10 IL1B PLP1 TNF
29 12.25 IFNG MMP9 TNF TNFRSF1A
30 12.23 CCL2 ICAM1 IFNG IL1B MMP9 TNF
31
Show member pathways
12.18 IFNG IL10 IL17A IL1B TNF
32 12.17 IFNB1 IFNG IL1B TNF TNFRSF1A
33
Show member pathways
12.12 IFNG IL1B